Considering that type I NKT cells have been reported to be able to eliminate CD1d-expressing tumor cells via multiple pathways (79–83), it seems that CD1d on the cancer cells is mainly recognized by type I NKT cells, resulting in enhancement of tumor immunity. This evidence concerns the gene CD1D and neoplasm.